Send to

Choose Destination
Scand J Gastroenterol. 2019 Jul 2:1-6. doi: 10.1080/00365521.2019.1618910. [Epub ahead of print]

Is home monitoring of inflammatory bowel disease feasible? A randomized controlled study.

Author information

a Clinic of Gastroenterology , Helsinki University Hospital, Jorvi Hospital , Espoo , Finland.
b University of Helsinki and Helsinki University Hospital , Helsinki , Finland.
c Tampere University, Tampere University Hospital , Tampere , Finland.
d Department of Clinical Chemistry , University of Helsinki , Helsinki , Finland.
e Department of Medicine, Division of Gastroenterology , Helsinki University Hospital , Helsinki , Finland.


Objectives: The aim of this prospective study was to evaluate the home monitoring with a rapid fecal calprotectin test combined with a symptom questionnaire in patients with colonic IBD in real-life setting. Methods: We randomized 180 patients with colonic IBD in a study or a control group. The home monitoring patients performed the fecal calprotectin test and filled in a symptom questionnaire every second month and in cases with increasing symptoms. The control patients filled in the symptom questionnaire at baseline and at 6 and 12 months as well as for the appointment at the outpatient clinic. The study duration was 12 months. Results: The patient adherence to the self-monitoring program was low. Patients with a higher disease burden were more adherent than patients with better health-related quality of life, but otherwise, there were no significant factors predicting the adherence. The home monitoring patients had fewer contacts with the outpatient clinic, but otherwise, the disease course between the home monitoring and the control group were similar. Conclusions: The self-monitoring of IBD activity with a combination of a rapid fecal calprotectin home test and a symptom questionnaire provides an option for individualized care for IBD patients. However, adherence to the self-monitoring program remains a challenge.


Crohn´s disease; disease activity; fecal calprotectin; ulcerative colitis

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center